0001209191-23-035126.txt : 20230607 0001209191-23-035126.hdr.sgml : 20230607 20230607165031 ACCESSION NUMBER: 0001209191-23-035126 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230605 FILED AS OF DATE: 20230607 DATE AS OF CHANGE: 20230607 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Turner Christopher Durant CENTRAL INDEX KEY: 0001862146 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40671 FILM NUMBER: 23999601 MAIL ADDRESS: STREET 1: ONE BROADWAY, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nuvalent, Inc. CENTRAL INDEX KEY: 0001861560 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE BROADWAY, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 508-446-2272 MAIL ADDRESS: STREET 1: ONE BROADWAY, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-05 0 0001861560 Nuvalent, Inc. NUVL 0001862146 Turner Christopher Durant C/O NUVALENT, INC. ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142 0 1 0 0 Chief Medical Officer 1 Class A Common Stock 2023-06-05 4 M 0 10235 6.89 A 24748 D Class A Common Stock 2023-06-05 4 S 0 10235 44.86 D 14513 D Stock Option (Right to Buy) 6.89 2023-06-05 4 M 0 10235 0.00 D 2031-04-29 Class A Common Stock 10235 316430 D These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 21, 2021. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.80 to $45.02, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price. The shares underlying this option vest as follows: 25% of the shares vested on March 22, 2022, and the remainder have vested or shall vest over the next three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date. /s/ Deborah Ann Miller, attorney-in-fact 2023-06-07